Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GNRHR | P30968 | 20/20 | 0.51 |
| ▸ | TACR2 | P21452 | 1/20 | 0.36 |
| ▸ | HRH2 | P25021 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4509716 | 0.90 | GNRHR (0.63) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL4498457 | 0.78 | GNRHR (0.64) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL4469701 | 0.76 | GNRHR (0.51) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL3275447 | 0.75 | GNRHR (0.69) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL4507346 | 0.74 | GNRHR (0.64) | GNRHR | |
| SCHEMBL4464004 | 0.74 | GNRHR (0.51) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL4501488 | 0.73 | GNRHR (0.55) | GNRHRTACR2HRH2OPRM1OPRD1 | |
| SCHEMBL4492321 | 0.72 | PRKCI (0.41) | GNRHR | |
| SCHEMBL4496347 | 0.72 | GNRHR (0.66) | GNRHR | |
| SCHEMBL4506960 | 0.72 | GNRHR (0.65) | GNRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7582636-B2 | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor | WYETH (US) | 2009-09-01 | — | — | US | claimed |
| US-20060270848-A1 | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of gonadotropin releasing hormone receptor | WYETH (US) | 2006-11-30 | — | — | US | claimed |
| US-7582636-B2 | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor | WYETH (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582636-B2 | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor | WYETH (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582636-B2 | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of Gonadotropin Releasing Hormone receptor | WYETH (US) | 2009-09-01 | — | — | US | disclosed |
| US-20060270848-A1 | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of gonadotropin releasing hormone receptor | WYETH (US) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270848-A1 | Piperazinylimidazopyridine and piperazinyltriazolopyridine antagonists of gonadotropin releasing hormone receptor | GNRHR, PRLHR, FSHR | GNRHR 1/4885TACR2 128/4885HRH2 677/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.